However, when both drugs were combined, cell death was significantly increased in comparison with treatments alone, surpassing 60% of annexin-V+ cells in all tumor lines: ~70% in A549 cells, 60% in HT29 cells, and 80% in MCF7 cells (Figure 1B,D,F). The gene discussed is ANXA5; the disease is neoplasm.